Second Gubra-partnered obesity drug moves into Phase 2

Boehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, did not increase the risk of major cardiovascular events compared with placebo in the Phase 3 SYNCHRONIZE-CVOT trial. With this result, the registrational SYNCHRONIZE program in obesity is complete.

Full results from Novo’s Phase 3 ZEUS trial confirm that the IL-6 inhibitor ziltivekimab did not reduce the risk of heart attack, stroke or cardiovascular death in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation. The data were presented at the American Heart Association’s Scientific Sessions 2026 and published in the New England Journal of Medicine.

Finnish Herantis Pharma has extended the placebo-controlled period of its upcoming Phase II study of HER-096 in Parkinson’s disease. The company points to newly published evidence that smartphone-based motor assessments detect disease progression more sensitively than conventional clinical measures.

Uppsala-based Abera Bioscience has received approval from the Dutch Central Committee on Research Involving Human Subjects (CCMO) to start a Phase I trial of its nasal pneumococcal vaccine candidate Ab-01.12. The approval marks the company’s move from preclinical to clinical development.

Camurus has dosed the first patient in LUNAR-2, a randomized, double-blind, placebo-controlled Phase IIb study of CAM2056, its monthly semaglutide depot, in people with overweight or obesity.

Lytix Biopharma’s Phase II NeoLIPA study, which gives ruxotemitide with pembrolizumab before surgery in patients with resectable melanoma, has met its primary endpoint of pathological complete response (pCR).

Umecrine Cognition's golexanolone did not significantly improve cognition compared with placebo in a Phase 1b/2a trial in patients with primary biliary cholangitis (PBC). Majority owner KDventures is writing down its holding in the company to zero.